Table 2 AuNP-based formulations approved for clinical trials by FDA. Adapted from [19, 32]
From: Multifunctional Gold Nanoparticles for Improved Diagnostic and Therapeutic Applications: A Review
AuNP formulation | Condition or disease | Properties of the metallic NPs | NCT number |
|---|---|---|---|
Aurrimune | Late stage pancreatic, breast, colon, melanoma, sarcoma and lung cancer | 27 nm AuNPs core loaded with TNF-α and PEG | NCT00356980 NCT00436410 |
Aurolase | Refractory and/or recurrent tumors for head and neck cancer Primary and/or metastatic lung tumors | 150 nm silica-gold nanoshells coated with PEG | NCT00848042 NCT01679470 |
Sebacia Microparticles | Acne vulgaris | 150 nm silica-gold nanoshells coated with PEG | NCT02219074 NCT02217228 |
C19-A3 GNP peptide | Type 1 diabetes | AuNPs with peptide fragment related to insulin | NCT02837094 |
NU-0129 | Gliosarcoma | ||
Recurrent glioblastoma | AuNPs with nucleic acid | NCT03020017 | |
NANOM-FIM | Stable angina Heart failure Atherosclerosis | ||
Multivessel coronary artery disease | Silica- AuNPs vs AuNPs with silica–iron oxide shells with photothermic burning or melting effect onto the lesion | NCT01270139 | |
Nano Care Gold | Cavity pre-treatment in Caries class Ii | AgNPs and AuNPs in 70% isopropyl alcohol | NCT03669224 |
Exhaled Breath Olfactory Signature (Artificial Nose) | Pulmonary hypertension | AuNPs coated with organic ligands as sensor array for detection of volatile organic compounds in breath of patients | NCT02782026 |
Na-nose | Gastric diseases | Functionalized AuNPs and carbon nanotubes nanosensor arrays | NCT01420588 |
Nanomedical Artificial Olfactory System | Parkinson’s disease Parkinsonism | Functionalized AuNPs and carbon nanotubes nanosensor arrays | NCT01246336 |